AGC Biologics
21511 23rd Drive SE
Bothell
Washington
98021
United States
Tel: 425-485-1900
Website: http://www.agcbio.com/
About AGC Biologics
AGC Biologics is a leading global Contract Development and Manufacturing Organization, with a deep commitment to improving life quality by bringing new biopharmaceuticals to market. Because of our dedication to building and empowering our internal teams, AGC Biologics is an innovative leader in the industry with an extensive network of cGMP facilities in the US, Europe and Asia. As such, we deliver a deep expertise, dynamic solutions and technologies, as well as customized services for the scale-up and cGMP manufacturing of protein-based therapeutics. We forge exceptionally strong partnerships with our clients, and we never lose sight of our pledge to deliver a reliable and compliant drug substance supply, Right, On time. For more information, visit www.agcbio.com.
111 articles about AGC Biologics
-
AGC Biologics Milan Receives Special Award Mention by Confindustria for Research and Innovation
11/1/2023
AGC Biologics announced that the team at its Milan site has received a special mention for Research and Innovation led by Executives Under the Age of 40, one of six special mentions in the Business Prize for Innovation by Confindustria.
-
AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product
10/25/2023
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, announced a new service agreement with Medigene AG.
-
AGC Biologics Completes pDNA and mRNA Line Expansion in Heidelberg
10/12/2023
AGC Biologics today announced the completion of the facility expansion for its new plasmid DNA (pDNA) and messenger RNA (mRNA) production line at the CDMO’s Heidelberg, Germany site.
-
AGC Biologics Offers Guaranteed Delivery of at least 1e11 TU of LVV Material in Nine Months
9/14/2023
The CDMO expands its AGCellerate Program to provide Lentiviral vector support for advanced therapies developers
-
AGC Biologics Expands Cell Therapy Suites at Longmont ATMP Campus
8/23/2023
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, announced a capacity update with the addition of three new Grade B cell therapy suites to its Longmont, CO facility.
-
AGC Biologics Partners with Asahi Kasei Pharma Corporation on Clinical Antibody Project
8/15/2023
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, announced a new agreement with Asahi Kasei Pharma Corporation to produce clinical drug substance for antibody-based therapies at AGC Biologics’ Seattle manufacturing site.
-
AGC Biologics Completes Expansion at Milan Cell and Gene Therapy Development and Manufacturing Site
8/9/2023
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, announced the company completed the expansion of its manufacturing space at its Milan Cell & Gene Center of Excellence production site.
-
AGC Biologics Introduces AGCellerate, Offering Fast Timelines, Fixed Pricing and Guaranteed Product Quantity
6/5/2023
AGC Biologics today announced AGCellerate, a new program designed to deliver effective IND-ready GMP material for biopharmaceutical developers.
-
AGC Biologics Launches BravoAAV™ and ProntoLVV™ Platforms offering Flexible and Accelerated Vector Development and Manufacturing for Cell and Gene Therapy Programs
5/16/2023
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, announced the launch of its BravoAAV and ProntoLVV viral vector platforms.
-
AGC Biologics Received Bioprocessing Excellence Award in Japan
4/26/2023
AGC Biologics announced it has received the “Bioprocessing Excellence in Japan” award at the Asia-Pacific Bioprocessing Excellence Awards ceremony for the work and achievements at the AGC Biologics Chiba, Japan site.
-
AGC Biologics Signs Exosome Agreement with The Jikei University in Japan for Idiopathic Pulmonary Fibrosis (IPF) Project
4/3/2023
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it signed a service agreement with The Jikei University in Japan.
-
Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement
2/7/2023
Genenta Science has entered into a development and manufacturing service agreement (MSA) with AGC Biologics S.p.A. to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programs.
-
AGC Biologics and Gore Collaborate on New Protein A-based Purification Technology and Contract Manufacturing Services for Antibody Therapies
12/12/2022
AGC Biologics , a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a collaboration with W.L. Gore & Associates (Gore) that features Protein A affinity purification technology from Gore alongside the CDMO’s contract development and manufacturing services.
-
RoosterBio and AGC Biologics Announce Collaboration to Accelerate Manufacturing of Cell and Exosome Therapies
8/16/2022
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today a strategic partnership with RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cells (hMSCs), highly engineered media, and bioprocess development services.
-
AGC Biologics Supports Altheia Science’s Gene Therapy ProgramsThe CDMO’s Milan facility provides lentiviral vector and autologous CD34+ cell-based drug products for clinical testing
7/28/2022
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Altheia Science, a gene therapy company pioneering cell and gene therapy strategies to treat autoimmune diseases and cancer.
-
AGC Biologics Named Manufacturing Company of the year by American Business Awards
6/29/2022
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, announced it was named Company of the Year in the “Large - Manufacturing” category in the 20th Annual American Business Awards®.
-
AGC Biologics Supports Omicron-based Vaccine Candidate Manufacturing with Starting Material
2/9/2022
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, announced an expanded partnership to supply more plasmid DNA starting material for the Pfizer-BioNTech COVID-19 vaccine at the company’s Heidelberg facility.
-
BioSpace Movers & Shakers, Nov. 5
11/5/2021
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers. -
Biopharma and life sciences companies and organizations from across the globe provide updates on their businesses and pipelines.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.